Real-world experience of using ciclosporin-A 0.1% (Ikervis) in the management of ocular surface inflammatory diseases.

Rashmi DeshmukhDarren Shu Jeng TingAhmad ElsahnImran MohammedDalia G SaidHarminder Singh Singh Dua

Published in: The British journal of ophthalmology (2021)

Ikervis is a useful steroid-sparing topical treatment for managing OSIDs in the real-world setting. Preparations with improved tolerability are needed to benefit a larger number of patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
prognostic factors
open label
clinical trial
study protocol